Riik: Euroopa Liit
keel: inglise
Allikas: EMA (European Medicines Agency)
Pretomanid
Mylan IRE Healthcare Limited
J04
pretomanid
Antimycobacterials
Tuberculosis, Multidrug-Resistant
Dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Revision: 9
Authorised
2020-07-31
28 B. PACKAGE LEAFLET 29 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT DOVPRELA 200 MG TABLETS PRETOMANID This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, pharmacist or nurse. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Dovprela is and what it is used for 2. What you need to know before you take Dovprela 3. How to take Dovprela 4. Possible side effects 5. How to store Dovprela 6. Contents of the pack and other information 1. WHAT DOVPRELA IS AND WHAT IT IS USED FOR Dovprela contains the active substance pretomanid, a type of antibiotic. Antibiotics are medicines used to kill bacteria that cause diseases. Dovprela is used in combination with two other medicines called linezolid and bedaquiline to treat tuberculosis that affects the lungs, when the disease has become resistant to many other antibiotics: • extensively drug resistant tuberculosis or • treatment-intolerant or multidrug-resistant tuberculosis It is used in adults 18 years and over. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE DOVPRELA DO NOT TAKE DOVPRELA • if you are allergic to pretomanid, antibiotics of the group called nitroimidazoles, or any of the other ingredients of this medicine (listed in section 6) Since pretomanid must be used in combination with other medicines against tuberculosis – linezolid and bedaquiline – please make sure that you Lugege kogu dokumenti
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Dovprela 200 mg tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 200 mg pretomanid. Excipient with known effect Each tablet contains 294 mg lactose (as monohydrate) and 5 mg sodium. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablets. White to off-white oval tablet debossed with M on one side and P200 on the other side. Tablet dimensions: 18 × 9 mm. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (XDR), or treatment-intolerant or nonresponsive multidrug- resistant (MDR) tuberculosis (TB), see sections 4.2, 4.4 and 5.1. Consideration should be given to official guidance on the appropriate use of antibacterial agents. _ _ 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment with pretomanid should be initiated and monitored by a physician experienced in the management of multidrug-resistant tuberculosis. Pretomanid should be administered by directly observed therapy (DOT) or in accordance with local practice. Posology The recommended dosage is 200 mg (one tablet) pretomanid once daily, for 26 weeks. A longer duration of therapy may be considered in patients who have not responded adequately to treatment at 26 weeks on a case by case basis (see section 5.1). Pretomanid should be administered only in combination with bedaquiline (400 mg once daily for 2 weeks followed by 200 mg 3 times per week [with at least 48 hours between doses] orally for a total of 26 weeks) and linezolid (600 mg daily orally for up to 26 weeks). 3 The product information for bedaquiline and linezolid should be consulted for a Lugege kogu dokumenti